Health Care Archives - Page 45 of 478

2 minute read

Alkermes’ Sleeping Disorder Studies’ Data Look Excellent, Analyst Says

April 9, 2:23 PM

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.

ALKS

1 minute read

Why Is Moderna Stock Trading Higher On Tuesday?

By Vandana Singh

April 9, 2:16 PM

Moderna stock jumps post AACR 2024 presentation of mRNA-4157 + Keytruda data in advanced HPV-negative head and neck carcinoma. Positive responses in the Phase 1 trial, with a 27.3% objective response rate and 63.6% disease control rate. Promising results and ongoing trials.

MRK

2 minute read

Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists

By Vandana Singh

April 9, 2:13 PM

Unlock AI-powered radiology solutions with Bayer AG and Google Cloud collaboration. Accelerate medical imaging innovations with gen AI tools for faster diagnoses.

BAYRY

1 minute read

Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report

By Nabaparna Bhattacharya

April 9, 12:33 PM

Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to reshape its workforce and tap local talent pools.

NVS

2 minute read

Pfizer Seeks Expanded Use Of Abrysvo As Vaccine Shows Potential In 18+ Patients

By Vandana Singh

April 9, 12:20 PM

Discover pivotal Phase 3 trial results for Pfizer's Abrysvo vaccine in adults 18-59 at risk of severe RSV disease. Achieved immunogenicity and safety milestones pave the way for potential regulatory approval, addressing a critical unmet need.

PFE

2 minute read

Why Is Penny Stock Biophytis Trading Higher On Tuesday?

By Vandana Singh

April 9, 10:06 AM

Announcing OBA clinical development program by Biophytis with BIO101 (20-hydroxyecdysone) for obesity treatment. Phase 2 study expected mid-2024, with efficacy results anticipated in 2025.

BPTS

2 minute read

EXCLUSIVE: PainReform’s Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions

By Vandana Singh

April 9, 8:30 AM

PainReform reveals superior IVR rates of PRF-110 vs. competitors in post-surgical pain management. Findings showcase PRF-110's extended analgesic effect potential, reducing opiate dependency.

PRFX

2 minute read

Analysts Express Confidence in Alnylam’s Hypertension Drug Despite Mixed Trial Data

By Vandana Singh

April 8, 2:37 PM

The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood pressure with standard-of-care antihypertensives.

ALNY

2 minute read

Johnson & Johnson’s Carvykti Stands Ahead Of Bristol Myers’ Rival Blood Cancer Therapy With FDA Approval For Wider Population

By Vandana Singh

April 8, 2:19 PM

FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration efforts.

JNJ

2 minute read

Bristol Myers Squibb’s Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation

By Vandana Singh

April 8, 2:00 PM

Bristol Myers Squibb's latest data on Krazati (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer. Promising objective response rates and progression-free survival. FDA priority review underway.

BMY